Research & Education

Adding Bevacizumab to Standard Treatment Improves Overall Survival in Patients with Malignant Pleural Mesothelioma

September 7, 2015

WCLC 2015

Contact: Jeff Wolf                                                                                                  Chris Martin                                       
IASLC Director of Communications                                                                   Public Relations Manager                 
Jeff.Wolf@IASLC.org | 720-325-2952                                                              CMartin331@comcast.net | 630-670-2745                                                                                                  

Becky Bunn
IASLC Projects Specialist
Becky.Bunn@IASLC.org | 720-325-2946

 

Adding Bevacizumab to Standard Treatment Improves Overall Survival in Patients with Malignant Pleural Mesothelioma

DENVER, Colo. — Adding the angiogenesis inhibitor bevacizumab to standard treatment for malignant pleural mesothelioma (MPM) increases life expectancy without severe toxicity, according to research presented today at 16th World Conference on Lung Cancer (WCLC) hosted by the International Association of the Study of Lung Cancer (IASLC). The French multicenter randomized phase 3 trial data was presented by Dr. Arnaud Scherpereel, Head of the Pulmonary and Thoracic Oncology Department and Professor at the University Hospital (CHU) of Lille, France.   

Pleural mesothelioma arises from the tissue lining that surrounds the lungs, and often causes chest pain under the rib cage, painful coughing, shortness of breath and unexplained weight loss. Bevacizumab inhibits the ligand vascular endothelial growth factor (VEGF), which is a potent mitogen for MPM cells.

Between 2008 and 2014, 73 centers enrolled 448 patients in the study. One group received standard chemotherapy for MPM and the second group received standard chemotherapy with bevacizumab.

Scherpereel and colleagues found that the addition of bevacizumab to standard chemotherapy increased the median overall survival to 18.8 months compared to 16 months with standard chemotherapy. The progression-free survival was also improved with bevacizumab.

“Bevacizumab addition to pemetrexed/cis-platin provides a significantly longer survival in patients with MPM, with acceptable toxicity, making this triplet a new treatment paradigm,” Scherpereel reported.

 

About the WCLC:

The WCLC is the world’s largest meeting dedicated to lung cancer and other thoracic malignancies, attracting more than 7,000 researchers, physicians and specialists from more than 100 countries. The conference goal is to increase awareness and collaboration so that the latest developments in lung cancer can be understood and implemented throughout the world. Falling under the theme of “Fighting Lung Cancer,” the conference will cover a wide range of disciplines and unveil several research studies and clinical trial results. For the first time, IASLC has invited survivors to attend the conference free of charge. For more information on the 2015 WCLC, visit: http://wclc2015.iaslc.org/.

About the IASLC:

The International Association for the Study of Lung Cancer (IASLC) is the only global organization specifically dedicated to the study of lung cancer. Founded in 1974, the association's membership includes nearly 4,000 lung cancer specialists in 80 countries. For more information, visit: https://www.iaslc.org/.